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Abstract
Background: Interstitial lung diseases (ILDs) are associated with a high burden of disease. However, data on the
prognostic impact of comorbidities and comorbidity-related pharmaceutical treatments in patients with various
ILDs remain sparse.
Methods: Using longitudinal claims data from a German Statutory Health Insurance Fund, we assessed comorbidity
in ILD subtypes and associated drug treatments. Baseline comorbidity was assessed via the Elixhauser Comorbidity
Index that was amended by ILD-relevant conditions. Drug treatment was assessed on the substance level using the
ATC-codes of drugs prescribed at the time of ILD diagnosis. Subsequently, the comorbid conditions (main analysis)
and pharmaceutical substances (secondary analysis) with a meaningful association to survival were identified for
the complete ILD cohort and within the subtype strata. For this, we applied multivariate Cox models using a LASSO
selection process and visualized the findings within comorbidomes.
Results: In the 36,821 patients with ILDs, chronic obstructive pulmonary disease (COPD), arterial hypertension, and
ischaemic heart disease (IHD) were the most prevalent comorbidities. The majority of patients with cardiovascular
diseases received pharmaceutical treatment, while, in other relevant comorbidities, treatment quotas were low
(COPD 46%, gastro-oesophageal reflux disease 65%). Comorbidities had a clinically meaningful detrimental effect on
survival that tended to be more pronounced in the case of untreated conditions (e.g. hazard ratios for treated IHD
0.97 vs. 1.33 for untreated IHD). Moreover, comorbidity impact varied substantially between distinct subtypes.
Conclusions: Our analyses suggest that comorbid conditions and their treatment profile significantly affect
mortality in various ILDs. Therefore, comprehensive comorbidity assessment and management remains important in
any ILD.
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Background
Interstitial lung diseases (ILDs) comprise around 200
different rare diseases that are mostly associated with
high mortality but are heterogeneous regarding aeti-
ology, prognosis, and treatment [1].
Recent clinical trials have created a sound basis for
improved pharmaceutical treatment of patients with
idiopathic pulmonary fibrosis (IPF) [2, 3]. However, the
transferability of corresponding findings to routine care
settings remains slightly uncertain [4]. This has also been
highlighted in other diseases such as chronic obstructive
pulmonary disease (COPD), in which comorbidities play a
significant role in management decisions and clinical out-
come [5]. Assuming that a similar interaction between co-
morbidity and outcomes in various ILD subtypes exists,
more research is currently being conducted. These
investigations are urgently recommended because the re-
lationships between an index disease (here: ILD) and co-
morbidities include conditions that occur incidentally (e.g.
arterial hypertension) as well as potential risk factors (e.g.
gastro-oesophageal reflux) or complications respectively
sequelae of the index disease (e.g. pulmonary hyperten-
sion). These different interaction modes therefore intro-
duce a high level of complexity [6].
Available evidence suggests that comorbidities sub-
stantially affect disease progression and survival in IPF
[7, 8], but information on other ILD subtypes is sparse
[9, 10]. Moreover, previous research has often focused
on distinct conditions [11–14] instead of the patients’
entire comorbidity burden [15–17] and, consequently,
has tended to disregard the effects of pharmaceutical co-
morbidity management [8, 10, 18–21]. Against this back-
ground, we assessed the baseline comorbidity profile of
patients diagnosed with different ILD subtypes with a
particular emphasis on the impact of distinct comor-
bid conditions and their respective pharmaceutical treat-
ments on mortality. Since this study is the first to
elucidate the associations of treated vs. untreated comor-
bidity and mortality in distinct ILD subtypes this new as-
pect may improve patient-centred ILD management.
Methods
Data set and sample selection
We performed a retrospective analysis of anonymized
2009–2014 patient-level insurance claims data provided
by the Scientific Institute of AOK Statutory Health In-
surance funds (WIdO). AOK insures about 30% of the
German resident population, and the patient clientele is
considered to be representative for Germany [22].
Data analyses were conducted according to national
data protection laws, and AOK Bavaria approved the use
of their data for the following analyses. As we performed a
retrospective analysis of completely anonymised data, the
consultation of an ethics committee was not required for
this kind of analysis [23]. Data included in- and outpatient
diagnoses based on ICD-10 codes, procedures undertaken
based on the International Classification of Procedures in
Medicine for inpatients, item codes from the schedule of
fees for the outpatient sector, as well as information on
age and gender.
Our initial dataset contained all adult insurees with a
diagnosis of (a) idiopathic interstitial pneumonia (IIP)
[J84.1], (b) other fibrosing ILDs (OFI) [J84.0, J84.8, J84.9,
D48.1], (c) sarcoidosis (SARC) [D86.0–D86.9], (d) drug-
associated ILDs (DAI) [J70.2–J70.4], (e) pneumoconiosis
(PNE) [J62.0–J62.8, J63.0–J63.8], (f ) radiation-associated
pneumonitis (RAP) [J70.1], (g) eosinophilic pneumonia
(EPP) [J82], (h) hypersensitivity pneumonitis (HP) [J67.9]
and (i) connective tissue-associated ILD (CTD) [J99.1].
As a reference for our selection algorithm, we trans-
ferred the ICD-9-based validation algorithm of Esposito
et al. - that yielded a positive predictive value of 83.3% in
IPF-patients [24] - into ICD-10-codes. To avoid false-
positive diagnoses by non-specialists, we excluded individ-
uals without confirmed outpatient diagnoses from a pul-
monologist, an internal specialist, or a rheumatologist (for
the latter CTD only) and without any inpatient diagnosis.
Subsequently, other individuals who did not undergo at
least one relevant diagnostic procedure (bronchoscopy,
computerized tomography of the lungs (CT), pulmonary
function testing, and assessment of autoantibodies) during
the visit of the diagnosis were also excluded. Likewise, in-
dividuals with implausible diagnostic patterns (exclusion
of ILD after confirmed diagnosis, radiation-associated
pneumonitis without previous/concurrent diagnosis of
malignancy, CTD without previous/concurrent diagnosis
of autoimmune disease) were excluded.
According to Walsh et al., the agreement on distinct
ILD subtypes between different specialists and specia-
lised ILD teams is limited [25]. Accordingly discrepant
diagnoses of a patient’s ILD impedes a precise assess-
ment of subtype specific comorbidity profiles. Therefore,
in the next step, we excluded individuals assigned to dif-
ferent ILDs simultaneously. In addition, we omitted pa-
tients with inconclusive information on gender or date
of birth and individuals with an interrupted sequence of
AOK enrolment. Finally, patients with a first ILD diag-
nosis in 2014 were excluded, leaving 58,364 individuals.
Those with a minimum observation period of 12 months
before ILD diagnosis were classified as incident and the
remainder as prevalent cases (Fig. 1).
Assessment of variables with time reference
Portrayed as the difference between the date of diagnosis
and the date of death or the end of the observation period,
survival was our primary outcome parameter. Owing to
data protection laws, available information contained only
the month and year of death. Thus, the date of death was
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set on the 15th of each month for individuals deceased be-
fore 31 December 2014. Individuals surviving beyond this
date were considered as censored.
Within the German health care system, outpatient
diagnoses are not reported with their exact date but per
quarter of the year. To define the date of diagnosis, we
first assessed the quarter within which the first ILD diag-
nosis was performed (QDiag) and, subsequently, chose
the middle of each quarter. Given that the thus defined
date of diagnosis is to some extent imprecise for some
patients, the date of diagnosis might be before the date
of death. To avoid the exclusion of those patients who
have a survival time of up to 0 days, we assigned them a
fictional survival of 1 week.
Assessment of comorbidity and medication profiles
The comorbidity burden at baseline was operationalized via
the Elixhauser Index (EI) [26]. The EI was implemented
using the ICD-10 coding algorithm of Quan et al. [27]. EI
distinguishes between hypertension and diabetes with and
without complications. Individuals with codes for both
forms were assigned to the condition with complications.
Additionally, the EI was slightly modified to reflect the
ILD-related comorbidity more precisely. First, ‘pulmonary
hypertension’ (PH) was excluded from the EI domain ‘pul-
monary circulation disorders’ and analysed as a separate
condition; secondly ‘lung cancer’ was removed from the EI
domain ‘solid tumour without metastases’ and analysed as a
separate condition as well. We also considered the non-EI
conditions gastro-oesophageal reflux disease (GERD), ob-
structive sleep apnoea syndrome (OSAS), ischaemic heart
disease (IHD), and thromboembolism based on previous
evidence on their ILD relevance [15, 16, 28]. Each patient
with at least one corresponding inpatient or one confirmed
outpatient diagnostic code during QDiag was classified as
suffering from that condition.
Fig. 1 Consort diagram of sample selection
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Comorbidity-relevant medication accounted for (a) ‘drugs
against heart insufficiency’ (digitalis glycosides, diuretics,
anti-arrhythmic drugs); (b) ‘drugs against cardiovascular
diseases’ (statins, beta-blockers, acetylcholinesterase inhibi-
tors [ACE inhibitors], angiotensin-I-antagonists); (c) ‘anti-
acid drugs’ (proton-pump inhibitors [PPI], histamine-H2
blockers); (d) ‘anti-clotting medication’ (antiplatelet drugs,
heparin (−derivates), vitamin-K antagonists – but no novel
oral anti-coagulant drugs [NOACs] owing to their low pre-
scription rate [413 patients, 1.1%]); (e) ‘anti-diabetic agents’;
(f) ‘anti-depressants’; (g) ‘drugs for obstructive airway
disease’ (long-acting beta2 agonists [LABA], long-acting
muscarinic antagonists [LAMA], inhalative corticosteroids
[ICS] and their combinations); and (h) ‘drugs for treatment
of pulmonary hypertension’ (sildenafil, prostaglandin, bosen-
tan, ambrisentan, sitaxentan, tadalafil, further referred to as
specific PH drugs). The comorbidity-relevant medication
was assessed based on the Anatomical Therapeutic Chem-
ical (ATC) codes of substances prescribed during QDiag.
For details, see Table 2.
Patients were assumed to be treated if a diagnosis was
combined with at least one prescription for any thera-
peutic substance using the following combinations: (a)
congestive heart failure: beta-blockers, ACE inhibitors,
angiotensin-I-antagonists, digitalis glycosides, diuretic
drugs; (b) cardiac arrhythmia: digitalis glycosides, anti-
arrhythmic drugs, beta-blockers; (c) IHD: statins, beta-
blockers, ACE inhibitors, angiotensin-I-antagonists, anti-
platelet drugs, vitamin-K antagonists, heparin (−derivates);
(d) valvular disease: beta-blockers, ACE inhibitors, digitalis
glycosides; (e) hypertension: beta-blockers, ACE inhibi-
tors, angiotensin-I-antagonists, diuretic drugs; (f) periph-
eral vascular disorders: antiplatelet drugs, vitamin-K
antagonists, heparin (−derivates), statins; (g) diabetes:
anti-diabetic agents; (h) GERD: PPI, histamine-H2
blockers; (i) COPD: LABA, LAMA, ICS or combinations;
(j) PH: specific PH drugs, diuretics; and (k) depression:
anti-depressants.
Statistical analysis
For the complete ILD cohort as well as stratified by sub-
type, we assessed baseline characteristics, comorbid con-
ditions, and medication profiles in a descriptive analysis.
Subsequently, we identified associations between comor-
bidity, treatment pattern, and survival via multivariate Cox
models [29] with age, gender, and subtype as pre-fixed co-
variates. Comorbid conditions were classified as ‘treated’
and ‘untreated’ depending on the patients’ medication pro-
files. These findings were visualized in the form of a ‘comor-
bidome’, which combines information on hazard ratios
(HRs) and comorbidity prevalence [8, 30]. A drug-extended
Cox model including the pharmaceutical substances pre-
scribed was performed as secondary analysis. Comorbid
conditions respectively pharmaceutical substances consid-
ered in this selection process are further referred to as im-
pact factors.
For variable selection, we included all conditions with a
prevalence of at least 5.0% and relied on the LASSO
method [31, 32], which can manage collinear input vari-
ables quite efficiently [33]. To calculate HRs, 95% confi-
dence intervals (CI), and p-values, which are not part of
LASSO itself, we ran ‘traditional’ Cox models with the co-
variates identified by LASSO. This procedure has been ac-
cepted to address issues of multiple testing adequately [34].
To check the robustness of our results, we performed
two sensitivity analyses (SA). Considering the chronic na-
ture of the comorbid conditions, we extended the obser-
vation timeframe for SA1 to the four quarters before
QDiag. Moreover, we required a minimum of two out-
patient diagnoses within two different quarters or at least
one inpatient diagnosis. For drug prescriptions, a mini-
mum of two prescriptions within two different quarters
during the respective timeframe was required. For SA2,
the four quarters from QDiag until three quarters after
QDiag were screened for confirmed outpatient and in-
patient ILD diagnoses. Only patients with a minimum of
two diagnoses within at least two quarters were included.
If a patient died during the prospective observation
period, ILD diagnoses were required in all quarters ob-
served with a maximum of one quarter without an ILD
diagnosis. All analyses were performed at a significance
level of 5% using the software packages SAS, version 9.3,
and R, version 3.3.3. Comorbidomes were constructed
using Microsoft Excel, version 2010.
Results
Population characteristics
Among the 36,821 patients identified, 13,985 received
their diagnosis by a pulmonologist, 20 patients who had
CTD were diagnosed by a rheumatologist, and 15,731
had inpatient diagnoses. Another 6338 individuals re-
ceived both outpatient specialist and inpatient diagnoses.
Seven hundred forty-seven patients were diagnosed by
an internal specialist only.
The complete ILD cohort predominantly consisted of
individuals with IIP (n = 14,453; 39.3%), sarcoidosis (n
= 9106; 24.7%), and other fibrosing ILDs (n = 7187; 19.
5%), while all other ILD-subtypes combined accounted
for 6075 individuals (16.5%). The mean age at diagnosis
was 66.0 years and 29,704 ILD-patients were male. The
number of comorbid conditions ranged between 0 (4.
4% of the population) and 18. Median survival was 29.
0 months with a death rate of 31.0% (Table 1). Higher
comorbidity burden was associated with increased mor-
tality (Additional file 1: Figure S1).
Information on subtype-specific characteristics can be
found in Additional file 2: Table S1.
Schwarzkopf et al. Respiratory Research  (2018) 19:73 Page 4 of 15
Comorbidity profile and associated medication
Having a prevalence below 5% excluded ‘pulmonary cir-
culation disorders (excluding PH)’, ‘paralysis’, ‘other
neurological disorders’, ‘peptic ulcer disease’, ‘AIDS/HIV’,
‘lymphoma’, ‘blood loss anaemia’, ‘alcohol abuse’, ‘drug
abuse’, ‘psychoses’, and ‘thromboembolism’.
More than half the patients had ‘COPD’ or ‘uncompli-
cated hypertension’ and almost one third had IHD (Fig. 2).
These conditions were also the most prevalent in the dis-
tinct subtypes. ‘Metastatic cancer’, ‘coagulopathy’, and ‘defi-
ciency anaemia’ were of low prevalence, whereas the ILD-
relevant conditions ‘lung cancer’, ‘PH’, and ‘OSAS’ were ob-
served in 6.3%, 7.9%, and 6.4% of the patients, respectively.
The comorbidity profiles observed for distinct ILD sub-
types resembled those within the total cohort except for a
substantially higher prevalence of ‘metastatic cancer’ and
‘solid tumours’ in radiation-associated pneumonitis and of
‘rheumatoid arthritis/connective tissue disorder in CTD
(Additional file 3: Table S2).
Prescription rates of comorbidity-relevant drugs
(Table 2) generally ranged below the corresponding co-
morbidity prevalence. For 6 out of 13 comorbid condi-
tions, more than one third of the patients did not
receive any related drug treatment. ‘Lack of treatment’
was particularly pronounced for ‘depression’, ‘diabetes
without complications’, and ‘COPD’, for which only a mi-
nority of patients received comorbidity-relevant drugs
(35.8%, 39.1%, 46.0% respectively). In contrast, almost all
patients with cardiac or cardiovascular diseases had re-
lated drug prescriptions. However, the prescription rates
for the distinct substances at disposal varied substan-
tially (Table 3). This general trend was largely transfer-
able to the distinct subtypes (Additional file 4: Table S3).
Associations between clinical characteristics and mortality
The comorbidity-only Cox model (columns two and three
of Table 4) and the drug-extended Cox model (columns
four and five of Table 4) both revealed a significantly posi-
tive association of male gender, age, and non-sarcoidosis
ILDs with mortality. Both models yielded similar HRs,
whereupon the drug-extended model in general exhibited
slightly less pronounced associations. The mortality risk
was generally higher in untreated comorbid conditions
than in treated ones. Most conditions were negatively
associated with survival, but positive associations were ob-
served for ‘OSAS’, ‘treated valvular disease’, ‘treated hyper-
tension with complications’, ‘obesity’, ‘hypothyroidism’,
‘treated GERD’, and ‘rheumatoid arthritis/connective tissue
disorder’ in both Cox models. For the comorbidity-only
Cox model, corresponding findings are visualized as a
comorbidome (Fig. 3). Referring to the drug-extended
Cox model ‘Statins’, ‘beta-blockers’, ‘ACE inhibitors’, ‘angio-
tensin-I-antagonists’, ‘anti-arrhythmic drugs’, ‘heparin
(−derivates)’ and ‘ICS’ showed an independent positive as-
sociation, whereas ‘diuretics’, ‘antiplatelet drugs’, ‘PPIs’, ‘H2-
antagonists’, ‘specific PH drugs’, and ‘anti-depressants’ dem-
onstrated a negative association with survival.
Within the analyses stratified by subtype (Additional file 4:
Table S3), all significant effects mirrored the total cohort,
yet the pre-selected impact factors and the judgement of
their significance differed substantially by ILD subtypes.
Additionally, we found no positive association between any
comorbid condition and survival for drug-associated ILD,
radiation-associated pneumonitis, and HP, and only a single
positive association for sarcoidosis (‘OSAS’), pneumoconi-
osis (‘OSAS’), and CTD (‘treated valvular disease’). Likewise,
we identified just two positive associations for eosinophilic
pneumonia (‘treated hypertension with complications’,
‘treated IHD’). However, we discovered five positive associa-
tions for IIP (‘treated COPD’, ‘hypothyroidism’, ‘rheumatoid
arthritis/connective tissue disorder’, ‘obesity’, and ‘OSAS’)
and six for other fibrosing ILDs (‘treated hypertension with-
out complications’, ‘treated COPD’, ‘rheumatoid arthritis/
connective tissue disorder, ‘obesity’, ‘untreated GERD’, and
‘OSAS’). Figure 4 summarizes the corresponding results for
IIP, other fibrosing ILDs, and sarcoidosis, whilst the comor-
bidomes for the remaining ILD-subtypes are represented as
Additional file 5: Figure S3.
The drug-extended models indicated an independent
advantageous impact of treatment with statins for IIP,
other fibrosing ILDs, sarcoidosis, pneumoconiosis, and
eosonophilic pneumonia and of treatment with heparin
Table 1 Baseline characteristics of the study sample
Study sample
N 36,817 %
Idiopathic interstitial pneumonias (IIP) 14,453 39.3
Other fibrosing ILDs (OFI) 7187 19.5
Sarcoidosis (SARC) 9106 24.7
Drug-associated ILDs (DAI) 407 1.1
Pneumoconiosis (PNE) 1579 4.3
Radiation-associated pneumonitis (RAP) 464 1.3
Eosinophilic pneumonia (EPP) 1518 4.1
Hypersensitivity pneumonitis (HP) 967 2.6
Connective tissue disease-associated ILD (CTD) 1140 3.1
Ø age (years) at diagnosis (SD) 66.0 14.6
Male gender 20,704 56.2
Ø survival in months (SD) 29.6 0.31
Dead at end of observation period 11,422 31.0
Median number of comorbidities (IQR)a 5.0 [3.7]
Non-ILD-related hospitalization (%) during observation 24,665 67.0
ILD-related hospitalization (%) during observation 3304 9.0
All figures as N (%) unless reported otherwise
IQR, interquartile range, SD standard deviation
a31 comorbid conditions from the Elixhauser Index amended by PH, lung
cancer, GERD, IHD, thrombosis, and OSAS yields a maximum of 37
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(−derivates) for IIP, other fibrosing ILDs, sarcoidosis, and
pneumoconiosis. In contrast to the total cohort analysis,
antiplatelet drugs had no detrimental association with sur-
vival in any subtype, whereas vitamin-K antagonists were
associated with increased mortality in radiation-associated
pneumonitis. Moreover, an increased mortality risk was
observed for patients with other fibrosing ILDs treated
with histamine-H2 antagonists and for sarcoidosis pa-
tients treated with PPIs; however, the PPI treatment
was associated with a survival benefit among CTD pa-
tients (Additional file 6: Table S4).
Sensitivity analyses
Details on the SAs are found within Additional files 6, 7,
8, and 9: Tables S4–S7 and Additional file 10: Figure S2.
Sensitivity Analyses 1 (SA1)
For all conditions except for ‘COPD’ and ‘fluid and elec-
trolyte disorders’ prevalence rates were similar to the
main analysis. Prescription rates of comorbidity-relevant
drugs were reduced particularly for statins and COPD-
related drugs.
Comparing the comorbidity-only Cox model to the
main analysis, ‘treated COPD’ and ‘treated diabetes with
complications’ lost their significance, whereas ‘liver dis-
ease’ gained significance. For the drug-extended Cox
model, the exclusion of ‘lung cancer’ during the LASSO
selection process and a highly significant positive
association of ‘treated diabetes without complications’
with survival were the only relevant differences regarding
comorbid conditions. Moreover, referring to comorbidity-
relevant drugs, the beneficial impact of heparin-(derivates)
observed in the main analysis could not be replicated.
Sensitivity Analyses 2 (SA2)
Twenty-one thousand five hundred eighty-one individuals
were considered for the SA2, but neither the age and gen-
der distribution nor the median observation period for
this population differed from the main analysis. Comor-
bidity prevalence differed only marginally but the sample
presented lower proportions of comorbidity treatment. In
contrast to the main analysis, ‘treated diabetes without
complications’ and ‘untreated hypertension with complica-
tions’ demonstrated a significant detrimental association
in the comorbidity-only Cox model, whereas ‘treated
hypertension without complications’ and ‘hypothyroidism’
lost their beneficial effect. Moreover, the negative impact
of ‘treated diabetes with complications’ could not be trans-
ferred from the main analysis to SA2. Regarding the drug-
extended Cox model highly significant positive associa-
tions of treated as well as untreated COPD were the only
noteworthy differences from the main analysis.
Fig. 2 Comorbidity profile for the total cohort accounting for conditions with a prevalence ≥5.0%
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Discussion
Our study emphasizes the relevance of comorbidities
and their consequent treatment across various ILDs.
The results obtained through this study suggest the need
for improving comprehensive pharmaceutical comorbidity
management in ILDs, with a particular emphasis on the
treatment of ILD-relevant comorbid conditions such as
COPD (54.0% untreated) and GERD (35.1% untreated).
Moreover, we perceived ILD subtype-specific comorbidity
profiles. In this regard, the current ICD-10 coding system
needs to be acknowledged as not being sufficiently differ-
entiated to precisely separate distinct fibrosing ILDs from
one another. Therefore, patients in the IIP and the other
fibrosing ILDs group may be substantially more heteroge-
neous than in the other subtypes. Although within less
frequent subtypes sample size issues might explain the
observed differences, the LASSO method, which selects
conditions based on relevance and not just on signifi-
cance, provided first insights into subtype-specific comor-
bidity management approaches.
As expected, highly prevalent, potentially age-associated
comorbid conditions were not necessarily those with the
strongest impact on survival [35–37]. Yet generally, we
observed a clinically meaningful association with a higher
mortality risk in the case of untreated distinct comorbidi-
ties. This emphasizes the need for active screening for and
treatment of comorbidity in distinct ILDs. This might be
highlighted by using the example of PH, which is recog-
nised as a marker of diseases progression and prognosis in
ILDs. PH frequently complicated the course of many ILDs
depicted in our data and was identified as a crucial impact
factor for all subtypes but radiation-associated pneumon-
itis. However, the advantage of specific PH drugs remains
unclear. Recent trials have not only failed to demonstrate
a benefit of PH-drugs but even reported potential detri-
mental effects in IPF [38]. Thus, treatment options are
limited. Our data show that most patients are treated ac-
cording to clinical practice with diuretics (96% of treated
PH patients), while the use of PH drugs is low (14% of
treated PH patients). Only in the subgroup of CTD-ILD
and PH did 57% of the treated patients receive specific PH
drugs that complied with current guidelines [39].
‘COPD’, ‘treated hypertension’, rheumatoid arthritis/
connective tissue disorders’, and ‘OSAS’ were positively
associated with survival in the complete cohort, but this
was generally not the case on the level of the distinct
ILD strata. Observations regarding ‘COPD’ and ‘treated
hypertension’ might be explained by an early detection
bias. This means that individuals with a known chronic
condition are under frequent medical control, which in-
creases the likelihood of earlier ILD diagnosis or that
symptoms related to the comorbid condition yield an
earlier detection of the ILD. In part, this explanation also
applies to ‘rheumatoid arthritis/connective tissue disor-
ders’ that can manifest as CTD-ILDs. Yet from a clinical
point of view, this comorbidity should not occur in other
subtypes. In contrast, a recent study concerning OSAS
reports that CPAP therapy enhances the capability of
IPF patients to perform activities of daily living, and the
authors also proposed a mitigating effect on mortality
[40], which corresponds with our own observation on
the general impact of OSAS.
In addition to investigating the associations of comor-
bidity prevalence and its treatment to survival, we ana-
lysed the independent impact of distinct comorbidity-
related drugs. Currently, the role of anti-acid treatment
is particularly under discussion [7, 8, 41, 42]. As re-
ported before for IPF [7], we could not find an associ-
ation between anti-acid treatment and improved survival
among the distinct ILDs, yet we simultaneously observed
Table 2 Prescription patterns of comorbidity-relevant medication
at baseline
Individuals with prescriptions of therapeutic agents for
comorbid conditions
N %
Treatment of heart insufficiency/cardiac arrhythmia 11,267 30.6
Digitalis glycosides (ATC code C01AA) 1516 4.1
Anti-arrhythmic drugs (ATC code C01BD) 541 1.5
Diuretic drugs (ATC code C03) 10,631 28.8
Treatment of cardiovascular disease 19,376 52.6
Statins (ATC code C10AA) 5881 16.0
Beta-blockers (ATC code C07) 11,038 30.0
ACE inhibitors (ATC codes C09AA C09B) 9309 25.3
Antiotensin-I-antagonists (ATC codes C09CA C09D) 4664 12.7
Treatment with anti-clotting medication 7692 20.9
Antiplatelet drugs (ATC code B01AC) 4071 11.1
Vitamin-K antagonists (ATC code B01AB) 2428 6.60
Heparin (−derivates) (ATC code B01AA) 2285 6.2
Treatment with anti-acid drugs 14,596 39.6
Proton-pump inhibitors (PPI) (ATC code A02BC) 14,171 38.5
Histamine-H2 blockers (ATC code A02BA) 463 1.3
Treatment with anti-depressants (ATC code N06A) 3952 10.7
Treatment with anti-diabetic drugs
(ATC codes A10A, A10B)
5891 16.0
Treatment with drugs against obstructive airway disease 11,021 29.9
Long-acting beta2 agonists (LABA)
(ATC code R03AC)
2640 7.2
Long-acting muscarinic antagonists (LAMA)
(ATC code R03BB)
4690 12.7
Inhaled corticosteroids (ICS) (ATC code R03BA) 2794 7.6
Combination product LABA/ICS (ATC code R03AK) 5135 13.9
Combination product LABA/LAMA (ATC code R03AL) 40 0.1
Treatment with specific PH drugs (ATC codes G04BE03,
B01AC09, C03KX)
265 0.7
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Table 3 Proportion of treated comorbid conditions
Share of diagnosed individuals with comorbidity-relevant prescription at baseline
N diagnosed N treated % treated
Congestive heart failure (EI group 1) 10,793 9514 88.1
Beta-blockers 5093 53.5
ACE inhibitors 3995 42.0
Angiotensin-I-antagonists 1752 18.4
Digitalis glycosides 1038 10.9
Diuretic drugs 5114 53.8
Cardiac arrhythmia (EI group 2) 9694 5382 55.5
Beta-blockers 4769 88.6
Digitalis glycosides 1256 23.3
Anti-arrhythmic drugs 512 9.5
Valvular disease (EI group 3) 5345 3957 74.0
Beta-blockers 2536 64.1
ACE inhibitors 1806 45.6
Diuretic drugs 2691 68.0
IHD 11,632 9357 80.4
Statins 3761 40.2
Beta-blockers 5730 61.2
ACE inhibitors 4292 45.9
Angiotensin-I-antagonists 1971 21.1
Antiplatelet drugs 2986 31.9
Heparin (−derivates) 1157 12.4
Vitamin-K antagonists 1187 12.7
Hypertension without complications (EI group 6) 19,059 17,594 92.3
Beta-blockers 7255 41.2
ACE inhibitors 6433 36.6
Angiotensin-I-antagonists 3241 18.4
Diuretic drugs 4936 28.1
Hypertension with complications (EI group 7) 5866 5301 90.4
Beta-blockers 2813 53.1
ACE inhibitors 2221 41.9
Angiotensin-I-antagonists 1222 23.1
Diuretic drugs 2427 45.8
PH 4537 1771 39.0
PAH drugs 237 13.4
Diuretic drugs 1699 95.9
COPD (EI group 10) 20,595 9473 46.0
LABA 2431 25.7
LAMA 4376 46.2
ICS 2138 22.6
Peripheral vascular disorders (EI group 4) 6692 3391 50.7
Antiplatelet drugs 1566 46.2
Heparin (−derivates) 698 20.6
Vitamin-K antagonists 581 17.1
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an independent negative impact of anti-acid drugs in
other fibrosing ILDs and sarcoidosis, as previously shown
for IPF [8]. Reverse causality must be considered as an ex-
planatory factor to solve this apparent contradiction.
At the subtype level, we found no association between
antiplatelet drugs and survival [8]. Yet, there was a posi-
tive impact of heparin (−derivates) in IIP, other fibrosing
ILDs, sarcoidosis, and pneumoconiosis, but vitamin-K
antagonists had no significant impact on survival in any
subtype (except for radiation-associated pneumonitis).
This needs to be further investigated, as recent analyses
report a detrimental association between anticoagulants
and survival or disease progression [20, 43, 44]. These
studies focus on warfarin and IPF, whereas we studied all
forms of vitamin-K antagonists and heparins within sev-
eral ILD subtypes. Apparently, the role of anticoagulants
is not entirely understood and a detailed examination of
different drug entities is urgently required, especially for
subtypes other than IPF. Here, particularly the role of
NOACs – which were not included in our analyses as only
413 (1.1%) patients received corresponding prescriptions
– should be further investigated.
Although our observed positive impact of drugs for
the treatment of cardiovascular diseases supports recent
studies claiming benefits for statin therapy [21, 45], the
results of our analysis should be cautiously interpreted.
Different patient groups and methodological approaches
hamper a sound between-study comparison and our re-
search focuses on a claims data-based study [46].
Compared with studies from specialized ILD centres
[7, 8], our study displayed more frequent age-associated
comorbidities (e.g., arterial hypertension, IHD, diabetes).
Possibly, this display represents an incorporation of
diagnoses from primary, secondary, and tertiary care,
where priority setting for distinct conditions is assumed
to be different. Additionally, different patient cohorts
introduce substantial variation in regards to comorbidity
prevalence [16]. Thus, direct comparisons are a sensitive
issue. Moreover, the comorbidity burden was assessed
based on ICD-10 codes, which could produce potential
coding errors [47]. Furthermore, the coding practice
may be triggered to some extent by remuneration rele-
vance. One example could be the observed high preva-
lence of COPD, for which additional payments exist in
the form of disease management programme bonuses.
To ensure sound comorbidity diagnosis, we restricted
our analysis to confirmed diagnoses and required the
multiple documentation of comorbidity diagnoses within
SA1. Given the high concordance between the main ana-
lysis and SA1, we assume that the risk of false-positive
comorbidity diagnoses is of subordinated relevance.
Currently, the ICD coding system does not allow differ-
entiation between different IIPs and other fibrosing ILDs.
Since the documented codes could not be validated with
medical files, the possibility exists that some of the pa-
tients may have been misclassified. To some extent, this
possibility is supported by the unexpectedly high propor-
tion of individuals with eosinophilic pneumonia as well as
by the high share of individuals with comorbid 'rheuma-
toid arthritis/connective tissue disorders' in non-CTD-
ILDs. Here, the assignment of individuals with polyarthro-
pathy to other subtypes than CTD may result due to the
coding requirement that CTD-ILD should only be diag-
nosed in the presence of systemic connective tissue disor-
ders (ICD-10 codes M33-M335) but not in the case of
polyarthropathy (ICD10-code M11-M14). Indeed, we ob-
served a particularly high prevalence of polyarthropathy in
the heterogeneous subtypes of other fibrosing ILDs and
IIP and only within these two subtypes 'rheumatoid
arthritis/connective tissue disorders' presented a signifi-
cant association with survival. This suggests that the
assignment to distinct ILD-subtypes is more in accord-
ance with coding requirements than with a clinical per-
spective on aetiology, which might affect conclusions on
the associations between comorbidity presence and mor-
tality. This underscores that thorough differential diagnos-
tic of patients with ILDs is essential to initiate appropriate
ILD management.
To avoid using a misdiagnosis, we only allowed con-
firmed ILD diagnoses by medical specialists combined with
Table 3 Proportion of treated comorbid conditions (Continued)
Share of diagnosed individuals with comorbidity-relevant prescription at baseline
N diagnosed N treated % treated
Statins 1928 56.9
Diabetes without complications (EI group 11) 6403 2505 39.1
Diabetes with complications (EI group 12) 5025 3337 66.4
Depression (EI group 31) 7410 2656 35.8
GERD 5594 3629 64.9
PPI 3545 97.7
Histamin-H2 antagonists 5594 99 2.7
percentages at substance level refer to the treated population
EI Elixhauser Comorbidity Index
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Table 4 Association of comorbid conditions and respective treatments with survival according to Cox proportional hazard
regression models
Variable Comorbidity-only model Drug-extended model
HR 95% CI HR 95% CI
Comorbidity profile Congestive heart failure treated (EI group 1) 1.53*** [1.46;1.60] 1.50*** [1.43;1.58]
Congestive heart failure untreated (EI group 1) 1.58** [1.42;1.76] 1.53*** [1.39;1.68]
Cardiac arrhythmia treated (EI group 2) 1.03n.s. [0.98;1.08] Not selected
Cardiac arrhythmia untreated (EI group 2) Not selected 1.02ns [0.95;1.08]
Valvular disease treated (EI group 3) 0.93* [0.88;0.99] 0.95 [0.89;1.00]
Valvular disease untreated (EI group 3) 1.10* [1.01;1.21] 1.13**. [1.03;1.24]
Pulmonary hypertension treated 1.40*** [1.31;1.56] 1.22*** [1.13;1.31]
Pulmonary hypertension untreated 1.43*** [1.31;1.56] 1.55*** [1.42;1.70]
Peripheral vascular disorders treated (EI group 5) 1.11*** [1.05;1.18] 1.12*** [1.05;1.18]
Peripheral vascular disorders untreated (EI group 5) 1.13*** [1.07;1.20] 1.13*** [1.07;1.20]
Hypertension without complications treated (EI group 6) 0.80** [0.73;0.88] Not selected
Hypertension without complications untreated (EI group 6) Not selected 1.00 [0.94;1.05]
Hypertension with complications treated (EI group 7) 0.86*** [0.82;0.90] 0.89** [0.83;0.95]
Hypertension with complications untreated (EI group 7) 1.01ns [0.88;1.16] 0.86*** [0.75;0.97]
COPD treated (EI group 10) 0.91*** [0.86;0.95] 0.98ns [0.94;1.03]
COPD untreated (EI group 10) 0.97ns. [0.92;1.01] Not selected
Diabetes without complications treated (EI group 11) 1.09* [1.02;1.17] Not selected
Diabetes without complications untreated (EI group 11) 1.16** [1.10;1.22] 0.99ns [0.60;1.62]
Diabetes with complications treated (EI group 12) 1.12*** [1.06;1.20] 1.03ns [0.63;1.59]
Diabetes with complications untreated (EI group 12) 1.20*** [1.12;1.30] 1.19*** [1.11;1.28]
Hypothyroidism (EI group 13) 0.89*** [0.84;0.95] 0.90*** [0.85;0.95]
Renal failure (EI group 14) 1.27*** [1.21;1.33] 1.26*** [1.20;1.32]
Liver disease (EI group 15) 1.05ns. [1.00;1.11] 1.04ns [0.99;1.10]
Metastatic carcinoma (EI group 19) 2.51*** [2.35;2.67] 2.51*** [2.36;2.68]
Solid tumour without metastasis (EI group 20) 1.15*** [1.10;1.21] 1.15*** [1.10;1.21]
Rheumatoid Arthritis/Connective Tissue Disorder (EI group 21) 0.89*** [0.84;0.95] 0.88*** [0.83;0.94]
Coagulopathy (EI group 22) 1.40*** [1.32;1.49] 1.43*** [1.35;1.52]
Obesity (EI group 23) 0.87*** [0.83;0.92 0.90*** [0.83;0.94]
Weight loss (EI group 24) 1.56*** [1.46;1.66] 1.53*** [1.44;1.63]
Fluid and electrolyte disorders (EI group 25) 1.74** [1.67;1.82] 1.70*** [1.63;1.78]
Deficiency anaemia (EI group 27) 1.11** [1.04;1.19] 1.10** [1.03;1.18]
Depression treated (EI group 31) 1.07ns [1.00;1.15] 1.00ns [0.95;1.06]
Depression untreated (EI group 31) 0.99ns. [0.93;1.04] Not selected
IHD treated 0.97ns [0.93;1.01] Not selected
IHD untreated 1.33*** [1.24;1.42] 1.04*** [0.98;1.09]
GERD treated 0.92** [0.87;0.98] 0.89*** [0.83;0.95]
GERD untreated 0.92*. [0.84;0.99] 0.95ns [0.87;1.03]
OSAS 0.76*** [0.70;0.82] 0.77*** [0.71;0.84]
Lung cancer 1.86*** [1.74;1.98] 1.80*** [1.69;1.92]
Medication intake Digitalis glycosides 1.07ns [0.99;1.16]
Anti-arrhythmic drugs 0.86* [0.75;0.98]
Diuretic drugs 1.24*** [1.18;1.31]
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Table 4 Association of comorbid conditions and respective treatments with survival according to Cox proportional hazard
regression models (Continued)
Variable Comorbidity-only model Drug-extended model
HR 95% CI HR 95% CI
Statins 0.85*** [0.80;0.90]
Beta-blockers 0.92*** [0.88;0.97]
ACE inhibitors 0.83*** [0.79;0.87]
Angiotensin-I-antagonists 0.73*** [0.68;0.78]
Antiplatelet drugs 1.08* [1.02;1.15]
Heparin (−derivates) 0.84*** [0.98;1.11]
Vitamin-K antagonists 1.04ns [0.78;0.90]
Proton pump inhibitors 1.05* [1.00;1.09]
H2-antagonists 1.24** [1.07;1.43]
Treatment with anti-depressants 1.12*** [1.05;1.18
Treatment with anti-diabetic drugs 1.07ns [0.66;1.75]
Long-acting beta2 agonists (LABA) 0.98ns [0.91;1.05]
Long-acting muscarinic antagonists (LAMA) 1.05ns [1.00;1.11]
Inhaled corticosteroids (ICS) 0.89** [0.82;0.97]
Combination product LABA/ICS not selected
Combination product LABA/LAMA not selected
Specific PH drugs 1.85*** [1.56;2.18]
All figures adjusted for age, gender, and ILD subtype
Comorbidity-only Cox model: concordance = 0.790, R2 = 0.286; AIC = 219,409.6
Drug-extended Cox model: concordance = 0.794, R2 = 0.2904; AIC = 219,215.4
HR hazard ratio, CI confidence interval, EI Elixhauser Comorbidity Index
Significance codes: p < 0.001 ‘***’ | p < 0.01 ‘**’ | p < 0.05 ‘*’ | not significant ‘ns’. ‚ not selected: disregarded by LASSO selection
Fig. 3 ILD comorbidome based on results of the LASSO selection for the comorbidity-only Cox model
Schwarzkopf et al. Respiratory Research  (2018) 19:73 Page 11 of 15
related diagnostic procedures, applied specific code combi-
nations (radiation-associated pneumonitis + diagnosis of
malignacy, CTD+ diagnosis of autoimmune disease), and,
lastly, we disregarded patients diagnosed with multiple
forms of ILDs. Although misclassification of subtypes can-
not be excluded, the results of the main analysis correlated
well with those of SA2 that applied a prospective validation
of the initial ILD diagnosis. Therefore, we are convinced
that a misclassification of subtypes does not crucially affect
the associations found between comorbidity and survival.
Due to the lack of information on clinical parameters
from the claims data, we could not account for the
severity of the ILDs or that of comorbidities [46]. How-
ever, not included in our data was the baseline informa-
tion on lung function. Disease severity remains a major
impact factor on survival in ILDs. Therefore, this base-
line information on lung function should be considered
as an effect modificator because FVC and DLCO are
established predictors for survival, e.g. in IPF [48] or
SSc-related ILD [49]. Additional knowledge lacking from
the claims data were reliable ICD codes for lifestyle
factors such as smoking, dietary habits, and physical
activity. These factors could not be incorporated into the
analyses.
Moreover, the decision to pharmaceutically treat a co-
morbid condition depends on many factors such as the
medical need for treatment, the potential interactions of
treatment regimens, the patients’ individual performance
status, and patient/physician preferences. Without the
connection to medical files, the aspect of confounding
by indication is clearly acknowledged to avoid potential
misconclusions on treatment recommendations. How-
ever, even a connection with medical files cannot elimin-
ate issues of adherence, meaning that the prescription of
a distinct drug is not necessarily linked to the medica-
tion intake by the patient.
Likewise, we limited our research to baseline comorbid-
ity only and did not incorporate newly occurring condi-
tions in the course of the ILD. By this, further relevant
conditions may have been disregarded. For example, Hyld-
gaard et al. have shown that substantial comorbidities are
diagnosed after IPF-diagnosis but they only observed an
additional mortality risk for late onset of cardiovascular
diseases and not for other conditions [7]. Hence, baseline
Fig. 4 IIP, other fibrosing ILDs- and sarcoidosis-specific comorbidomes based on results of the LASSO selection for the comorbidity-only Cox model
Schwarzkopf et al. Respiratory Research  (2018) 19:73 Page 12 of 15
comorbidity restriction may presumably only affect the
magnitude of HRs but not general statements on signifi-
cance of the comorbidities reported.
Last, the nature of this analysis does not allow a distinc-
tion between ILD-related and non-ILD-related mortality.
Indeed, all-cause mortality might not reflect the impact of
distinct comorbid conditions on ILD-related mortality
comprehensively. In particular, the effects of conditions
that present substantial disease-specific lethality might be
overestimated. Given recent evidence on an enhanced
mortality effect of combined ILD and lung cancer [12, 50],
it seems justified to assume corresponding interactions for
other conditions as well.
In contrast, claims data remain less prone to selection
bias than primary data-based cohorts. Thus, a realistic pic-
ture of comorbidity burden and treatment practice in daily
routine care can be assumed. Moreover, large sample sizes
enable analysis of the comorbidity profiles of rare ILD
subtypes for which reference literature is sparse.
For enhanced ILD-management thorough comorbidity
assessment seems paramount: We based our assessment
on the Elixhauser Index which was amended by ILD-
relevant comorbidities (‘GERD’, ‘OSAS’, ‘PH’, and ‘lung can-
cer’). Other than the often applied Carlson Index [36], the
Elixhauser Index more stringently addresses chronic condi-
tions related to high morbidity but not necessarily to high
mortality [26]. Thus, our approach seems superior in the
field of ILDs, which are quite heterogeneous regarding their
survival prognosis.
To further alleviate management decisions, we finally dis-
entangled untreated and treated comorbidity in regards to
comorbidity-relevant drugs. In our opinion, this approach
appears to be preferable to a simple prevalence-based ana-
lysis (comorbidity yes/no) that might fail to detect the pecu-
liar relevance of pharmaceutical comorbidity management.
Conclusion
In conclusion, improved management of comorbidities
in ILDs should address all survival-relevant conditions
and not be limited to risk factors and sequelae. Conse-
quently, more stringent pharmaceutical treatment seems
to be advisable because our analyses provide first in-
sights that untreated comorbidity tends to affect survival
in the various ILDs more detrimentally than treated co-
morbidity. However, since insurance claims data do not
address clinical characteristics of ILD patients compre-
hensively, further analyses of clinical cohorts with more
differentiated information on ILD subtype and disease
severity is needed. To improve patient benefit meaning-
fully, detailed longitudinal investigations of the mutual
interactions between comorbidity and its treatment at
the substance level should be encouraged. In parallel, a
stronger emphasis could be dedicated to evaluating the
benefits of non-pharmacological disease management.
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